Your browser doesn't support javascript.
loading
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
de Gooijer, Cornedine J; van der Noort, Vincent; Stigt, Jos A; Baas, Paul; Biesma, Bonne; Cornelissen, Robin; van Walree, Nico; van Heemst, Robbert C; Soud, Magdolen Youssef-El; Groen, Harry J M; den Brekel, Agnes J Staal-van; Buikhuisen, Wieneke A; Bootsma, Gerben P; Dammeijer, Floris; van Tinteren, Harm; Lalezari, Ferry; Aerts, Joachim G; Burgers, Jacobus A.
Afiliação
  • de Gooijer CJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Stigt JA; Department of Pulmonary Diseases, Isala Hospital, Zwolle, Netherlands.
  • Baas P; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Biesma B; Department of Pulmonary Diseases, Jeroen Bosch Hospital, Den Bosch, Netherlands.
  • Cornelissen R; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • van Walree N; Department of Pulmonary Diseases, Amphia Hospital, Breda, Netherlands.
  • van Heemst RC; Department of Pulmonary Diseases, Deventer Hospital, Deventer, Netherlands.
  • Soud MY; Department of Lung Oncology, Maxima Medical Centre, Eindhoven, Netherlands.
  • Groen HJM; Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.
  • den Brekel AJS; Department of Pulmonary Diseases, Ziekenhuis groep Twente, Almelo, Netherlands.
  • Buikhuisen WA; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Bootsma GP; Department of Pulmonary Diseases, Zuyderland Medical Centre, Heerlen, Netherlands.
  • Dammeijer F; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • van Tinteren H; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Aerts JG; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Burgers JA; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: s.burgers@nki.nl.
Lancet Respir Med ; 9(6): 585-592, 2021 06.
Article em En | MEDLINE | ID: mdl-33515500
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desoxicitidina / Mesotelioma Maligno / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Lancet Respir Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desoxicitidina / Mesotelioma Maligno / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Lancet Respir Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda